The NY Center for the Prevention of Heart Disease has announced the availability of three advanced cardiac diagnostic services aimed at identifying heart attack and stroke risk before symptoms develop. The offerings include advanced cholesterol testing through Boston Heart Diagnostic Labs, coronary CT angiograms enhanced by Cleerly and Heartflow AI platforms, and long-term heart rhythm monitoring. According to the center, conventional screening tools may leave a substantial share of at-risk patients undetected — a gap these services are designed to address.
More information is available at https://www.thenyheartcenter.com
The announcement comes at a time when cardiovascular disease remains the leading cause of death in the U.S. The American Heart Association notes that as much as 80% of heart disease and stroke may be preventable through lifestyle changes and risk-factor management, yet many individuals at elevated risk go unidentified through routine screening. The NY Center for the Prevention of Heart Disease states that its expanded diagnostic offerings are intended to provide a more complete picture of cardiovascular health for patients in the New York area.
Boston Heart Diagnostic Labs offers testing that measures cholesterol particle size and function, inflammation markers, insulin resistance, and genetic risk factors. These measurements provide a more detailed view of cardiovascular and metabolic health than conventional panels, enabling more individualized risk stratification than standard cholesterol and LDL testing alone.
The center's imaging capabilities include Coronary CT Angiography (CCTA) enhanced by artificial intelligence platforms from Cleerly and Heartflow, which the center says can detect arterial plaque accumulation years before it produces symptoms. This imaging approach allows clinicians to assess coronary artery health with a level of detail not available through traditional stress testing or standard imaging.
Strokes are frequently caused by silent atrial fibrillation, a heart rhythm abnormality that often presents without symptoms. Prolonged cardiac monitoring has been shown to improve detection rates substantially — research from the EMBRACE trial found atrial fibrillation in 16% of patients monitored for 30 days, compared to only 3% with standard 24-hour monitoring.
The NY Center for the Prevention of Heart Disease states that once cardiovascular risk is accurately identified, most heart attacks may be preventable through diet changes, exercise, and targeted cholesterol management. The center's diagnostic services are designed to support this approach, giving clinicians and patients the information needed to take early preventive action.
For more details, visit https://www.thenyheartcenter.com